INTRODUCTION
The role of platelet transfusions (prophylactic or therapeutic) for managing patients with various platelet consumptive or destructive disorders including 1) thrombotic thrombocytopenic purpura (TTP) 2) heparin induced thrombocytopenia (HIT) and 3) immune thrombocytopenic purpura (ITP) is debated but remains largely undefined and underexplored.
While platelets are primary mediators of hemostasis at sites of endothelial trauma, there is emerging evidence of their role as mediators in inflammation and pathological thrombogenesis [1] [2] [3] [4] [5] . It has been hypothesized that platelet transfusions may potentially provoke fatal thrombotic events [6] [7] [8] [9] [10] , particularly arterial ones in TTP and HIT 10, 11 . In TTP, the principal histological abnormality is proposed to be a 'platelet microvascular thrombus 12, 13 . In HIT, the underlying physiology is due to the formation of a heparin-dependent anti-platelet factor immune complex resulting in immunological platelet activation and thrombin generation, and subsequent thrombocytopenia and thrombotic risk [14] [15] [16] .
The role of platelet transfusions in the management of ITP remains unclear. Transfused autologous and allogeneic platelets have shortened survival in ITP, suggesting that platelet transfusions may not be of clinical benefit in this condition 17, 18 . On the other hand, some case series of platelet transfusions alone, in massive doses, or in conjunction with IVIG, have demonstrated efficacy in increasing platelet counts and preventing or stopping bleeding in ITP patients [19] [20] [21] [22] . The 2011 American Society of Hematology Guidelines recommend that platelet
For personal use only. on September 12, 2017 . by guest www.bloodjournal.org From transfusions in ITP should be reserved for catastrophic hemorrhage or concurrent surgeries only 23 .
Based on the little available data, the quality of evidence either supporting or negating platelet transfusions in these disorders is generally limited to studies with small sample sizes and resultant inherent methodological limitations. Thus, evidence based platelet transfusion guidelines in platelet consumptive disorders are either non-existent or consensus statements based upon insufficient data. A recent systematic review of the clinical evidence of platelet transfusions by the AABB Platelet Transfusion Guidelines Panel highlighted the paucity of data guiding the use of platelet transfusions in these disorders 24 .
This study, using a nationally representative hospital discharge database, assessed the current platelet transfusions practices in hospitalized patients with these platelet consumptive disorders and their association if any, with various clinical outcomes including bleeding, venous and arterial thrombotic events, acute myocardial infarction, stroke and overall survival.
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METHODS:
Data Source: Data from the Nationwide Inpatient Sample (NIS) for the years 2007-2011 were merged and used for this study. The NIS is the largest all-payer inpatient database in the U.S., developed as part of the Healthcare Cost and Utilization Project (HCUP) by the Agency for Healthcare Research and Quality (AHRQ). NIS uses a multi-staged clustering design to provide a stratified probability sample of 20% of all hospital discharges among U.S. community hospitals (approximately 1000-1100 hospitals per year). Community hospitals, per definition of the American Hospital Association, are all non-federal, short-term general and specialty hospitals including academic medical centers. Children's hospitals are also represented in the survey 25 . HCUP has selected hospitals in NIS to be maximally representative and generate nationally representative estimates such as to include 40-47 states and represent 90-97% of the US population over the different years.
Information in NIS is de-identified data and includes one primary or principal diagnosis and up to 24 total secondary diagnosis codes, one primary and up to 14 secondary procedure codes, admission and discharge status, demographic information and hospital characteristics. The principal diagnosis, the chief reason that was responsible for the admission, is coded in the first diagnosis field. All-listed diagnoses (Dx1-Dx25) include principal diagnosis plus additional conditions that either develop during the course of hospitalization or may co-exist at the time of admission. Data on laboratory values and pharmacological therapies administered during the course of an inpatient stay are not available in the NIS. The 'unit of analysis' is a hospital discharge and not a specific patient. Thus, the same patient could have had multiple hospitalizations in a specific year and will be captured each time as a separate hospitalization.
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HCUP guidelines in granting the authors access to NIS data set were followed, and all authors signed the data-use agreement 26 . Clustering the patients by hospitals is expected to produce more reliable 95% confidence intervals (95% CI) by taking into account the inter-facility correlation of patient outcomes as outcomes are more likely to be similar within rather than across hospitals 28 and has reliably been used in more recent publications using the NIS 29 . identified by diagnosis codes V12.51, V12.52 or V12.55 were excluded. We further excluded hospitalizations which had any thrombosis/ thromboembolism listed as the primary admitting diagnosis (implying being already present at admission). Using the ICD-9 coding, we identified cases of intracranial hemorrhage (ICH), gastrointestinal bleed (GIB) and/or genitourinary bleed (GUB) as "bleeding" for the purpose of our analysis (Appendix 2).
Identification of discharges

Sensitivity Analyses
We performed the following sensitivity analyses to explore the robustness of our findings: 1) We restricted the hospitalizations with primary diagnoses of 'thrombotic microangiopathies' (ICD9- 20.9% ITP). The most common race was whites for each disease entity (Table 1) .
Platelet transfusions were reported in 10.1% of all hospitalizations for TTP, 7.1% for HIT and 25.8% for ITP. In each condition, platelets were more commonly administered to adults than children (p<0.01). The most common procedure performed in admissions with TTP was plasma exchange (64% of admissions). A simple plasma infusion was reported in 32.3% of TTP admissions. In 75.3% of the TTP admissions, either plasma exchange or plasma infusion was performed. In HIT and ITP, the most common procedures were RBC transfusion (16.6%), and IVIG administration (20.9%) respectively (Table 1) . Table 2 lists the major complications/co-morbidities documented during the hospitalization for each disease type. TTP, HIT and ITP had a bleeding event reported in 13.7%, 5.7% and 11.5% of the admissions, respectively. Among TTP and ITP, the most common bleeding type was GU bleeding (8.6% and 6.1%, respectively), while in HIT the most frequent bleeding type was GI bleeding 2.7%. CNS bleeding was reported at ~1% in TTP, ITP and HIT.
Among thrombotic complications/co-morbidities, HIT had the highest percentage of thrombotic events with 20.6% thrombotic events (17.6% venous, 3.4% arterial and 0.4% with both arterial and venous thromboses), TTP with 4.1% (3.8% venous and 0.3% arterial) and ITP had 0.9% (0.8% venous and 0.1% arterial). Likewise, HIT also had the highest frequency of AMI events (7.1%) followed by TTP (5.1%) and ITP (0.5%). TTP admissions had the highest percentage of stroke at 5.2% followed by HIT at 2.3% and ITP at 0.3% (Table 2 ).
There are significantly higher odds of platelet transfusion in patients with reported bleeding patients were not significantly associated with venous thrombosis, arterial thrombosis, AMI or stroke after adjustment for age and gender (Table 3, Figure 1 ).
All-cause in-hospital mortality for TTP, HIT and ITP admissions was 8.8%, 3.4% and 1.4%, respectively (Table 4 ). In admissions for TTP and HIT, platelet transfusions were associated with significantly higher odds of all-cause mortality after adjusting for age and gender with an adjOR of 2.0 (95%CI=1.3-3.0) and 5.2 (95%CI=2.6-10.5) for TTP and HIT, respectively. Platelet transfusions did not have any significant association with mortality in ITP admissions after adjusting for age and gender; adjOR 1.1 (95%CI=0.8-1.4) ( Table 4) .
Number Needed to Harm:
In HIT, there are 6.90% arterial thromboses those with platelet transfusions versus 3.06% in those without i.e. 3.84% extra thrombosis with platelet transfusions. Thus, for every 26 patients receiving platelet transfusions, we will expect one additional arterial thrombosis. In TTP, there are 1.79% arterial thromboses those with platelet transfusions versus 0.35% in those without.
Thus, for every 75 patients receiving platelet transfusions, we will expect one additional arterial thrombosis.
Sensitivity Analyses:
Restricting the thrombotic microangiopathies to admissions with concurrent plasma exchange as a marker for increased specificity of TTP diagnosis and treatment, we found similar results:
platelet transfusions were associated with higher age and gender adjusted odds of arterial thrombosis [adjOR 6.4 (95%CI=1.1-39.
3)] as well as mortality [adjOR 2.2 (95%CI=1.3-3.9)].
We also performed additional analyses using HIT as the 1) primary admitting diagnosis (n=1445) and 2) one of the top two discharge diagnoses (n= 3031). Platelet transfusions were associated with higher age and gender adjusted odds of arterial thrombosis in admissions with a After adjusting for severity/acuity using APR DRG severity indices, the relationship for platelet transfusions in TTP with arterial thrombosis (adjOR 10.8 (95%CI 1.1-82.8)) as well mortality (adjOR 2.5 (95%CI 1.2-5.33)) remained statistically significant and with a similar effect size.
However, the risk of AMI with platelet transfusion did not remain significant after this adjustment (adjOR 2.1 (95%CI 0.8-5.3)). Likewise, for HIT admissions, after adjusting for severity/acuity risk, there remained a significant association between platelet transfusions and arterial thrombosis (adjOR 2.8 (95% CI 1.01-7.9)) and mortality (adjOR 3.8 (95% CI 1.7-8.2)) respectively.
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DISCUSSION
In the absence of established efficacy of platelet transfusions in various platelet consumptive disorders as well as the inability to rule out harm, the justification of their use is highly controversial. Due to lack of high quality data, there are no definite evidence based practice guidelines for platelet transfusions in these conditions. Additionally, there is no literature supporting a specific platelet count to serve as a transfusion threshold metric. Consequently, there remains a large heterogeneity in the use of platelet transfusions in these disorders with the decision to transfuse based on individual provider preference or institutional recommendations at the best.
Our study provides the first comprehensive national estimates of platelet transfusion practices with the platelet consumptive disorders TTP, HIT and ITP. We hereby present results from the largest available in-patient database supporting a significant association between platelet transfusions and arterial thrombotic events in TTP and HIT independent of age, gender and clinical severity/acuity. Notably, no relationship was seen between platelet transfusions and 'venous' thrombotic events in either TTP or HIT. Additionally, platelet use was associated with documented bleeding as well as higher mortality, likely implying their utilization in sicker hospitalized patients. Platelet transfusions in TTP patients were also associated with moderately high odds of AMI. Platelet transfusions among ITP patients were not associated with venous or arterial thrombosis, AMI or any improvement in survival after adjustment for age and gender. It is important to note that these reported events occurred in patients who received platelets during
hospitalization; however, we do not know the temporality of events and if the transfusion preceded the event.
Platelet transfusions are typically not recommended for patients with TTP as they have been hypothesized to provoke fatal thrombotic events [6] [7] [8] . These published reports have held credibility due to 1) biologic basis of the hypothesis, 2) identification of a close temporal relationship between platelet transfusions and adverse outcomes and 3) autopsy analysis revealing that platelets were the principal component of the thrombotic lesion in TTP patients [6] [7] [8] 12 . The In HIT, formation of a heparin-dependent anti-platelet factor antibody results in immune mediated activation of platelets and increased thrombotic risk, particularly arterial, due to increased thrombin generation 9, 10 . The benefit of platelets is questionable as transfusions have . Also, there is increasing successful utilization of registry data and databases using validated claims based diagnoses to study outcomes for rare disorders like TTP and serve as excellent prototypes for research and patient care 51, 52 .
Importantly, the temporality of the various clinical outcomes studied (except mortality) in relation to the platelet transfusions cannot be assessed from this dataset. While we see increased association of platelet transfusions with bleeding complications in the data, we cannot exactly determine the benefit of platelet transfusion in improving/preventing bleeding outcomes.
Additionally, some of the diagnoses may be lack specificity e.g. not all TTP patients had plasma exchange therapy or plasma exchange may have been used only transiently in some
For personal use only. on September 12, 2017. by guest www.bloodjournal.org From patients. Also, as this report includes data from large academic centers as well as non-academic centers, there is a possibility that the true magnitude of the association between thrombotic complications and platelet transfusions among patients with severe ADAMTS13 deficiency might be under-reported. However, all the sensitivity analyses performed confirmed the primary results. Another limitation is the lack of laboratory data in NIS particularly the platelet count, which might be an important determinant of platelet transfusions trigger. Specifically, as outlined above, there could be confounding from the degree of thrombocytopenia but we could not address that in this study.
Conclusions:
Platelet transfusions are frequently administered to patients with platelet consumptive disorders including TTP, HIT and ITP. These data suggest that platelet transfusions are common and likely administered to sicker patients and those with clinical bleeding, and may be associated with higher odds of arterial thrombosis (but not venous thrombosis) and mortality among hospitalized patients with a diagnosis of TTP and HIT. Whether the platelet transfusions were directly responsible for these events or they serve as a surrogate marker for severity of illness cannot be absolutely determined. However, the results remained significant after adjusting for clinical severity/acuity. Future mechanistic studies exploring these relationships are warranted in these disorders. However, more reliable evidence from a randomized controlled trial may be very hard to obtain in these rare disorders with limited use of platelet transfusions. Until mechanistic studies or trials are available to demonstrate the efficacy and risks of platelet transfusions in TTP and HIT, platelets should be considered to be relatively contraindicated and used only for emergencies, invasive procedures, surgeries or severe or life threatening bleeding refractory to other therapies.
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